Letrozole Bluefish

Letrozole, the active ingredient in Letrozole Bluefish, is an aromatase inhibitor presented as a tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen‑driven tumor growth and improving disease outcomes.

GNH USA supplies Letrozole Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and individual orders to hospitals, pharmacies and clinical trial sites throughout the global market.

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

Hormone receptor‑positive breast cancer (adjuvant): Decreases risk of cancer recurrence after surgery. Metastatic hormone receptor‑positive breast cancer (postmenopausal): Delays disease progression and extends survival. Neoadjuvant therapy for estrogen‑dependent tumors (postmenopausal): Reduces tumor size before surgery.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Joint and muscle pain: arthralgia and myalgia. - Fatigue: reduced energy levels. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe osteoporosis: increased risk of bone fractures. - Liver function abnormalities: elevated transaminases. - Cardiovascular events: thrombosis or myocardial infarction.

When prescribing Letrozole, clinicians should observe several precautionary measures to ensure patient safety.

- Assess bone health: perform baseline densitometry and consider calcium/vitamin D supplementation. - Monitor liver enzymes: check hepatic function before initiation and periodically during therapy. - Evaluate cardiovascular risk: screen for hypertension, hyperlipidemia and prior thrombotic events. - Avoid use in pregnancy: Letrozole is contraindicated in pregnant women (Category X). - Adjust for drug interactions: review concomitant medications that affect CYP2A6 or CYP3A4 metabolism. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP2A6 inducers (e.g., rifampicin): may markedly reduce plasma concentrations of Letrozole. - Tamoxifen: concurrent use can antagonize the anti‑estrogenic effect of Letrozole. - Estrogen‑containing hormone therapy: diminishes therapeutic benefit and increases risk of estrogen‑related side effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase Letrozole exposure, requiring monitoring. - Anticoagulants (e.g., warfarin): potential for altered INR, necessitating regular coagulation checks. - Antidepressants (e.g., SSRIs): may affect hormone levels; observe for clinical changes.